175 related articles for article (PubMed ID: 37981834)
21. N-terminal arginylation generates a bimodal degron that modulates autophagic proteolysis.
Yoo YD; Mun SR; Ji CH; Sung KW; Kang KY; Heo AJ; Lee SH; An JY; Hwang J; Xie XQ; Ciechanover A; Kim BY; Kwon YT
Proc Natl Acad Sci U S A; 2018 Mar; 115(12):E2716-E2724. PubMed ID: 29507222
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
23. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
24. The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
Eda H; Aoki K; Kato S; Okawa Y; Takada K; Tanaka T; Marumo K; Ohkawa K
Eur J Haematol; 2010 Jul; 85(1):68-75. PubMed ID: 20192985
[TBL] [Abstract][Full Text] [Related]
25. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ
Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012
[TBL] [Abstract][Full Text] [Related]
26. The Calcineurin-TFEB-p62 Pathway Mediates the Activation of Cardiac Macroautophagy by Proteasomal Malfunction.
Pan B; Li J; Parajuli N; Tian Z; Wu P; Lewno MT; Zou J; Wang W; Bedford L; Mayer RJ; Fang J; Liu J; Cui T; Su H; Wang X
Circ Res; 2020 Jul; 127(4):502-518. PubMed ID: 32366200
[TBL] [Abstract][Full Text] [Related]
27. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
28. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
29. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
30. Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.
Kuroda Y; Koyama D; Kikuchi J; Mori S; Ichinohe T; Furukawa Y
Leuk Res; 2021 Dec; 111():106672. PubMed ID: 34332177
[TBL] [Abstract][Full Text] [Related]
31. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
Meister S; Frey B; Lang VR; Gaipl US; Schett G; Schlötzer-Schrehardt U; Voll RE
Neoplasia; 2010 Jul; 12(7):550-61. PubMed ID: 20651984
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.
Accardi F; Toscani D; Bolzoni M; Dalla Palma B; Aversa F; Giuliani N
Biomed Res Int; 2015; 2015():172458. PubMed ID: 26579531
[TBL] [Abstract][Full Text] [Related]
33. Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis.
Chandra A; Wang L; Young T; Zhong L; Tseng WJ; Levine MA; Cengel K; Liu XS; Zhang Y; Pignolo RJ; Qin L
FASEB J; 2018 Jan; 32(1):52-62. PubMed ID: 28860152
[TBL] [Abstract][Full Text] [Related]
34. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
Feng R; Oton A; Mapara MY; Anderson G; Belani C; Lentzsch S
Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
[TBL] [Abstract][Full Text] [Related]
35. A mitophagy inhibitor targeting p62 attenuates the leukemia-initiation potential of acute myeloid leukemia cells.
Li Y; Li Y; Yin J; Wang C; Yang M; Gu J; He M; Xu H; Fu W; Zhang W; Ru Y; Liu X; Li Y; Xin Y; Gao H; Xie X; Gao Y
Cancer Lett; 2021 Jul; 510():24-36. PubMed ID: 33862150
[TBL] [Abstract][Full Text] [Related]
36. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Chauhan D; Singh A; Brahmandam M; Podar K; Hideshima T; Richardson P; Munshi N; Palladino MA; Anderson KC
Blood; 2008 Feb; 111(3):1654-64. PubMed ID: 18006697
[TBL] [Abstract][Full Text] [Related]
37. Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model.
Suominen MI; Mäki-Jouppila J; Huhtinen A; Sjöholm B; Rissanen JP; Luostarinen A; Fagerlund KM; Alhoniemi E; Siemeister G; Mumberg D; Käkönen SM; Scholz A
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070363
[TBL] [Abstract][Full Text] [Related]
38.
Wu H; Liu C; Yang Q; Xin C; Du J; Sun F; Zhou L
Autophagy; 2020 Apr; 16(4):683-697. PubMed ID: 31242129
[TBL] [Abstract][Full Text] [Related]
39. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
40. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
Front Immunol; 2018; 9():2467. PubMed ID: 30410490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
